Surgery For Stroke Prevention — Cost, Top Hospitals & Success Rates | MyMedicPlus

Stroke is one of the leading causes of death and long-term disability worldwide, affecting approximately 15 million people annually. While most strokes are ischemic — caused by blockages in cerebral blood flow — approximately 85% are potentially preventable through a combination of lifestyle changes, medications, and when appropriate, surgical intervention. Surgery for stroke prevention encompasses a set of procedures designed to eliminate or reduce identifiable vascular risk factors before a stroke occurs (primary prevention) or to prevent further events after a transient ischaemic attack (TIA) or minor stroke (secondary prevention).

The most widely performed procedure is carotid endarterectomy (CEA), which removes atherosclerotic plaque from the internal carotid artery — one of the most common sources of emboli that can travel to the brain. Landmark randomised controlled trials including NASCET, ECST, and ACAS established the survival benefit of CEA over best medical therapy alone in appropriately selected patients, fundamentally changing the management of symptomatic carotid artery disease.

Beyond carotid surgery, the field of surgical stroke prevention has expanded to include carotid artery stenting (CAS) as a less invasive alternative, patent foramen ovale (PFO) closure for cryptogenic stroke in younger patients, extracranial-intracranial (EC-IC) bypass for complex cerebrovascular occlusive disease, and surgical or endovascular repair of cerebral aneurysms to prevent haemorrhagic strokes.

These interventions are not appropriate for every patient. The decision to pursue surgical stroke prevention requires careful evaluation of stroke risk, procedural risk, patient comorbidities, anatomical factors, and patient preferences — always within a multidisciplinary team including vascular surgeons, neurologists, neurosurgeons, and interventional radiologists.

Surgery for stroke prevention targets specific vascular and structural conditions that carry a documented risk of causing ischemic or haemorrhagic stroke. Accurate diagnosis of the underlying pathology is essential to selecting the correct surgical intervention.

Carotid Artery Disease

Atherosclerotic narrowing (stenosis) of the internal carotid artery, particularly at the carotid bifurcation in the neck, is responsible for approximately 20% of all ischemic strokes. Plaque rupture releases emboli that occlude cerebral vessels, causing stroke or TIA. Stenosis severity is graded by duplex ultrasound, CT angiography, or MR angiography:

• Symptomatic carotid stenosis: Stenosis of 50–99% in a patient who has had an ipsilateral TIA or non-disabling stroke. This carries the highest short-term risk of subsequent stroke (up to 20% in 2 weeks after a TIA) and the greatest benefit from CEA.
• Asymptomatic carotid stenosis: Stenosis of 60–99% without prior neurological symptoms. The absolute benefit of surgery is smaller, and careful patient selection (low perioperative risk, male sex, plaque morphology) guides the decision.

Patent Foramen Ovale (PFO)

A PFO is a persistence of the fetal communication between the right and left atria, present in approximately 25–30% of adults. In cryptogenic stroke (no identified cause) occurring in patients under 60, a PFO is found in up to 40–50% of cases, suggesting paradoxical embolism — venous thrombi passing through the PFO into the arterial circulation. Three major RCTs (CLOSE, REDUCE, RESPECT) confirmed that PFO closure significantly reduces recurrent cryptogenic stroke compared to antiplatelet therapy alone.

Unruptured Cerebral Aneurysms

Intracranial saccular aneurysms are found in approximately 3–5% of the population. Rupture causes subarachnoid haemorrhage (SAH), a devastating condition with 50% mortality and significant morbidity among survivors. Unruptured aneurysms discovered incidentally are assessed using the PHASES score and ISUIA data; larger aneurysms (>7 mm), those in specific locations (posterior communicating artery, posterior circulation), and growing aneurysms are typically treated to prevent rupture.

Intracranial Arterial Occlusive Disease

Progressive occlusion of intracranial arteries refractory to medical therapy may cause recurrent ischemic events. In selected patients with haemodynamic compromise, EC-IC bypass restores cerebral blood flow to at-risk territory.

Patient selection for stroke prevention surgery requires balancing the natural history of the untreated condition against the risk of the procedure itself. Several clinical parameters and validated scoring systems guide this decision.

Eligibility for Carotid Endarterectomy (CEA)

• Symptomatic stenosis 50–99%: Best evidence supports CEA within 2 weeks of a TIA or non-disabling stroke (NASCET criteria). Benefit is greatest for men, stenosis >70%, and patients under 75 years. Women with symptomatic stenosis 50–69% have smaller absolute benefit.
• Asymptomatic stenosis >60–70%: CEA is recommended only in centres with <3% perioperative stroke/death rate. Best medical therapy (BMT) with intensive statin and antiplatelet treatment may be comparable to surgery in some patients.
• Low surgical risk: Candidates should have no recent large stroke (large territory infarct within 6 weeks), no severe cardiac comorbidities (recent MI, unstable angina, severe heart failure), no contralateral carotid occlusion, and no prior ipsilateral neck surgery or radiation.
• Life expectancy >5 years: The benefit of CEA accumulates over years; patients with very limited life expectancy may not live long enough to realise the benefit.

Eligibility for Carotid Artery Stenting (CAS)

• Patients with symptomatic carotid stenosis who are at high surgical risk for CEA: previous neck surgery, radiation, contralateral carotid occlusion, severe cardiac disease, or surgically inaccessible lesion (high bifurcation).
• Age <70 is preferred as older patients have higher embolic risk during stenting due to calcified, friable plaque.

Eligibility for PFO Closure

• Age typically 18–60 years with a cryptogenic ischemic stroke (no identified cause after comprehensive workup).
• PFO confirmed by contrast echocardiography (bubble study) with significant right-to-left shunting.
• No alternative cause identified (no atrial fibrillation, no significant carotid disease, no cardioembolic source).
• RoPE score >6 suggests high probability that stroke was PFO-related.

Eligibility for Aneurysm Treatment

• Aneurysm size >7 mm (or smaller in specific locations or patients with prior SAH).
• Aneurysm morphology suggesting instability (irregular shape, daughter sac, growth on serial imaging).
• Patient age and health permitting treatment with acceptable procedural risk.

Several surgical and endovascular techniques are available for stroke prevention. Selection depends on the underlying vascular pathology, anatomical characteristics, and the patient's risk profile.

Carotid Endarterectomy (CEA)

The gold-standard surgical procedure for carotid artery disease. Under general or regional (cervical block) anesthesia, the surgeon makes a longitudinal incision in the neck over the carotid artery, clamps the vessel, opens it, and physically removes the atherosclerotic plaque. A patch (Dacron, bovine pericardium, or saphenous vein) is typically used to close the artery and prevent restenosis. The procedure takes approximately 1.5–2.5 hours. Intraoperative transcranial Doppler monitoring detects emboli and haemodynamic compromise. Eversion endarterectomy is an alternative technique with comparable outcomes.

Carotid Artery Stenting (CAS)

A minimally invasive catheter-based procedure performed under local anesthesia and conscious sedation. A guiding catheter is advanced from the femoral or radial artery to the common carotid artery. A distal embolic protection device (filter or flow-reversal system) is deployed to capture debris released during stenting. A self-expanding nitinol stent is then placed across the stenosis to maintain luminal patency. CAS is associated with higher peri-procedural stroke rates than CEA in symptomatic patients (based on ICSS and CREST trials) but is preferred in high-surgical-risk patients.

Patent Foramen Ovale (PFO) Closure

Transcatheter PFO closure is performed under echocardiographic and fluoroscopic guidance, typically using the Amplatzer PFO Occluder or Cardioform device. A catheter is passed transvenously and through the PFO to deploy a double-disc device that seals the defect. The procedure is performed under conscious sedation, takes 30–60 minutes, and typically requires only one overnight stay. The device becomes covered with endothelium over 3–6 months, providing permanent closure.

Cerebral Aneurysm Treatment

• Surgical clipping: Open craniotomy to place a titanium clip across the aneurysm neck, excluding it from the cerebral circulation. Provides definitive, durable treatment.
• Endovascular coiling: Platinum coils are packed into the aneurysm sac via catheter to induce thrombosis, preventing rupture. Less invasive than clipping. Complex wide-neck aneurysms may require stent-assisted coiling or flow-diverter devices (Pipeline, Silk).

Extracranial-Intracranial (EC-IC) Bypass

Microsurgical anastomosis of an extracranial artery (typically the superficial temporal artery) to a branch of the middle cerebral artery, supplementing blood supply to ischemic brain territory. Reserved for patients with symptomatic haemodynamic compromise refractory to medical therapy.

The evidence base for surgical stroke prevention is robust, built upon multiple large, prospective randomised controlled trials and long-term registry data. The benefits are greatest in high-risk patients with correctly identified and treated pathology.

Carotid Endarterectomy Benefits

• Stroke risk reduction: In symptomatic patients with 70–99% stenosis, CEA reduces the absolute risk of ipsilateral stroke by approximately 16% over 5 years compared to medical therapy alone (NASCET data), equating to 1 stroke prevented for every 6 patients treated.
• TIA prevention: CEA virtually eliminates ipsilateral TIAs, which carry a 10–15% short-term stroke risk if untreated.
• Durable benefit: The protective effect of CEA persists for at least 10–15 years in follow-up studies, with no significant restenosis in most patients treated with patch closure.
• Mortality benefit: Long-term all-cause mortality is lower in surgically treated symptomatic patients when perioperative risk is below 6%.

PFO Closure Benefits

• Recurrent stroke reduction: The CLOSE trial showed a 97% relative risk reduction in recurrent stroke with PFO closure plus antiplatelet therapy vs. antiplatelet alone. REDUCE showed an absolute risk reduction of 3.9% over 2 years.
• Migraine with aura: Some evidence (MIST, PRIMA trials) suggests PFO closure may reduce frequency of migraine with aura, though this remains an off-label indication.
• Freedom from anticoagulation: Successful PFO closure allows cessation of long-term anticoagulation in most patients, reducing bleeding risks associated with indefinite warfarin or DOAC therapy.

Aneurysm Treatment Benefits

• Successful occlusion eliminates the risk of aneurysm rupture and SAH — which carries 50% mortality and severe disability in 25% of survivors.
• Modern endovascular techniques (coiling, flow diversion) achieve complete or near-complete aneurysm occlusion in 85–95% of appropriately selected cases.

All stroke prevention surgeries carry procedural risks that must be weighed against the natural history of the untreated condition. For CEA in symptomatic stenosis, surgery is beneficial only when the combined perioperative stroke and death rate is below 6% (symptomatic) or 3% (asymptomatic).

Carotid Endarterectomy Risks

• Perioperative stroke: The most feared complication, caused by intraoperative embolism or carotid thrombosis. Combined stroke/death rate should be <3% (asymptomatic) and <6% (symptomatic) for surgery to be beneficial. Experienced centres achieve rates of 1–2%.
• Cranial nerve injury: The facial nerve marginal mandibular branch, hypoglossal nerve, vagus nerve, and accessory nerve are all at risk during dissection. Transient neuropraxia occurs in 5–8% of cases; permanent injury is rare (<1%).
• Wound haematoma: Post-operative haematoma at the neck incision occurs in 3–5% of patients. Expanding haematomas can compress the airway and require urgent surgical evacuation.
• Carotid restenosis: Re-narrowing of the endarterectomised segment occurs in 5–10% of patients over 5 years. Patch closure significantly reduces this risk. Restenosis is usually asymptomatic and managed medically.
• Myocardial infarction: Cardiac events are the leading cause of perioperative mortality in CEA patients, who typically have significant systemic atherosclerosis. Pre-operative cardiac optimisation is essential.

Carotid Stenting Risks

• Higher peri-procedural stroke risk compared to CEA in symptomatic patients (>70 years), attributed to emboli released during plaque manipulation. Embolic protection devices reduce but do not eliminate this risk.
• Higher in-stent restenosis rate vs. CEA (10–15% vs. 3–5% at 3 years).

PFO Closure Risks

• Device embolisation or malposition (<1%), atrial arrhythmias (new-onset atrial fibrillation in 2–5%), pericardial effusion, and residual shunting requiring repeat procedure.
• The 90-day antiplatelet dual therapy period carries a small bleeding risk.

Aneurysm Treatment Risks

• Surgical clipping: 1–2% mortality and 3–5% morbidity in experienced centres for unruptured aneurysms.
• Endovascular coiling: 1–2% mortality, residual aneurysm requiring re-treatment in 20–30% of cases at 5 years.

Post-operative follow-up after surgical stroke prevention is essential not only to monitor healing but to optimise the medical management of vascular risk factors that reduce long-term stroke risk.

After Carotid Endarterectomy

• Hospital stay: Most patients are observed in a high-dependency or monitored setting for 12–24 hours post-operatively, then transferred to a standard ward. Discharge is typically on day 1–2 after an uncomplicated procedure.
• First two weeks: Patients should rest, avoid heavy lifting (>5 kg), and refrain from driving for 2–4 weeks (or as per local regulations). A soft diet is recommended for the first week if neck wound swallowing discomfort is present.
• Wound care: The neck incision is checked at 5–10 days for healing, haematoma, or wound infection. Most sutures are absorbable and do not require removal.
• Anti-platelet therapy: Aspirin 75–100 mg daily (already ongoing) is continued indefinitely. Dual antiplatelet therapy is not routinely used post-CEA unless there is a specific indication.
• Duplex surveillance: Carotid duplex ultrasound at 1 month, 6 months, and annually thereafter to monitor for restenosis or contralateral progression.
• Risk factor management: Statin therapy, blood pressure control (target <140/90 mmHg, or <130/80 mmHg if tolerated), glycaemic control in diabetics, smoking cessation, and regular physical activity are all mandatory long-term interventions.

After PFO Closure

• Dual antiplatelet therapy (aspirin + clopidogrel) for 3–6 months while the device endothelialises, then aspirin alone for 1–2 years.
• Transthoracic echocardiogram at 6 months to assess device position and residual shunting.
• Activity restriction for 1–2 weeks; return to normal activities and exercise typically by 2–4 weeks.
• Long-term follow-up with neurology and cardiology annually for the first 3–5 years.

After Aneurysm Treatment

• Imaging surveillance (CTA or MRA) at 3 months, 1 year, and 3–5 years to assess occlusion durability and detect coil compaction or residual filling.
• Post-clipping surveillance is generally needed every 5 years with CTA or MRA.

The cost of stroke prevention surgery varies considerably by procedure type, country, hospital type, and insurance coverage. As these are generally medically necessary procedures with documented outcome benefits, most are covered by health insurance plans when clinical criteria are met.

Carotid Endarterectomy (CEA) Costs

• United States: USD 15,000–40,000 inclusive of surgeon, anesthesia, hospital, and monitoring fees. With Medicare, patient out-of-pocket cost depends on supplement coverage.
• United Kingdom (NHS): Covered fully for eligible patients with symptomatic carotid stenosis. Private care: GBP 8,000–15,000.
• India (accredited hospitals): USD 3,000–7,000 at JCI/NABH-accredited centres such as Apollo, Fortis, Narayana Health, or Medanta — with equivalent quality and experienced vascular surgical teams.
• Thailand / Singapore: USD 6,000–14,000 depending on hospital tier.

Carotid Artery Stenting (CAS) Costs

• USA: USD 18,000–45,000 (device costs add significantly to stenting expenses).
• India: USD 4,000–9,000 including stent and embolic protection device.

PFO Closure Costs

• USA: USD 10,000–25,000 (device + catheterisation laboratory fees). Covered by most major insurers for cryptogenic stroke with RoPE score >6.
• India: USD 3,500–7,000 using Amplatzer or Occlutech devices.

Cerebral Aneurysm Treatment Costs

• Surgical clipping (USA): USD 30,000–80,000 due to neurosurgical team fees, ICU stay, and monitoring.
• Endovascular coiling (USA): USD 25,000–60,000.
• India: USD 5,000–15,000 for either approach at top neurosurgical centres.

Key Cost Determinants

• Procedure type (open surgery vs. endovascular)
• Device costs (stents, occluder devices, coils)
• Length of hospital stay and ICU requirement
• Need for general anesthesia vs. local/sedation
• Pre-operative imaging workup (CTA, MRA, DSA)
• Post-operative rehabilitation and surveillance

Best medical therapy (BMT) has improved dramatically over the past two decades and is the backbone of stroke prevention regardless of whether surgery is performed. For some patients, BMT alone may be equivalent or preferable to surgery.

Antiplatelet Therapy

Aspirin (75–100 mg daily) reduces ischemic stroke risk by approximately 20–25% in high-risk patients. Clopidogrel is an alternative for aspirin-intolerant patients or in combination (dual antiplatelet therapy) for short-term use after TIA (the POINT and CHANCE trials established 21-day dual therapy after minor stroke/TIA reduces recurrent events by ~25%). Ticagrelor is an option in specific high-risk scenarios.

Anticoagulation

For cardioembolic stroke (atrial fibrillation, patent foramen ovale), oral anticoagulation (warfarin or direct oral anticoagulants — DOACs — including apixaban, rivaroxaban, dabigatran, edoxaban) significantly reduces stroke risk. DOACs reduce stroke risk by 19–26% relative to warfarin in atrial fibrillation, with lower intracranial haemorrhage rates. Anticoagulation alone (rather than PFO closure surgery) is an option for PFO-related cryptogenic stroke in patients over 60 or those with small shunts.

Intensive Statin Therapy

High-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) reduce carotid plaque progression, stabilise vulnerable plaque, and reduce stroke risk by 20–30% independent of cholesterol lowering. The SPARCL trial demonstrated that atorvastatin 80 mg post-stroke reduced recurrent stroke by 16% versus placebo. Statins are recommended in all patients with atherosclerotic carotid disease regardless of surgery.

Blood Pressure Control

Every 10 mmHg reduction in systolic blood pressure reduces stroke risk by approximately 27% across all stroke subtypes. ACE inhibitors, ARBs, and thiazide diuretics are first-line agents. Target BP is below 130/80 mmHg in high-risk patients (AHA/ASA 2021 guidelines).

Lifestyle Modifications

• Smoking cessation: reduces stroke risk by 50% within 1–2 years.
• Mediterranean diet or DASH diet: associated with 30–40% reduction in cardiovascular events.
• Moderate aerobic exercise (>150 minutes/week): reduces BP, improves lipid profile, and lowers stroke risk.
• Alcohol moderation: heavy drinking (>2 units/day) significantly raises stroke risk.

For asymptomatic carotid stenosis in particular, the latest evidence from the CREST-2 trial (2025) suggests that intensive BMT may be equivalent to revascularisation, prompting re-evaluation of surgical thresholds — underscoring the importance of individualised decision-making.